Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07485179 · ClinicalTrials.gov registry record
Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases
A clinical trial of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 770
- Enrollment target
- 1
- Study location
NCT07485179 is a study of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 770 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07485179, a study of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 770 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions Studied
Interventions
- DRUG Initiation of pembrolizumab
- DRUG Initiation of chemotherapy
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Somerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2027-03-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07485179
The ClinicalTrials.gov registry entry for NCT07485179 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Initiation of pembrolizumab is the first listed.
NCT07485179 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07485179 about?
NCT07485179 is a clinical study titled "Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07485179?
This trial is currently active not recruiting. The enrollment target is 770 participants. The study started on 2026-03-12. Estimated completion is 2027-03-12.
What conditions does trial NCT07485179 study?
This clinical trial studies the following conditions: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07485179?
The interventions under investigation include: Initiation of pembrolizumab (DRUG), Initiation of chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07485179?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07485179 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.